<DOC>
	<DOCNO>NCT01193348</DOCNO>
	<brief_summary>The primary purpose ass efficacy safety eculizumab pediatric patient aHUS control TMA characterize thrombocytopenia , hemolysis renal impairment .</brief_summary>
	<brief_title>An Open-Label , Multi-Center Clinical Trial Eculizumab Pediatric Patients With Atypical Hemolytic-Uremic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>Inclusion : 1 . Patient 's parent/legal guardian must willing able give write informed consent patient must willing give write informed assent ( applicable determine central IRB/IEC ) . 2 . Pediatric patient aHUS : Patients could newly diagnose , previously diagnose disease , postkidney transplant disease . 3 . Patients one month 18 year body weight ≥ 5kg . 4 . Platelet count screen baseline visit must lower limit normal ( &lt; LLN ) . If screening visit baseline visit combine one day , additional platelet count value obtain least 24 hour screening/baseline sample must also &lt; LLN . 5 . Exhibited sign symptom hemolysis start current aHUS event ( i.e. , lactate dehydrogenase ( LDH ) ≥1.5 x Upper Limit Normal [ ULN ] hemoglobin ≤LLN ) , fragment RBC negative Coombs test . 6 . Serum Creatinine level ≥97 percentile age screening ( patient require dialysis acute renal failure also eligible ) . 7 . Patients aHUS due complement regulatory protein genetic abnormality anticomplement factor antibody know etiology hemolytic uremic syndrome ( HUS ) rule confirm Exclusion Criteria . 8 . Patients must vaccinate N. meningitidis , pneumococcus haemophilus ( per vaccine label ) least 14 day prior study drug initiation otherwise protect prophylactic antibiotic . Patients age two year receive antibiotic prophylaxis throughout treatment period . 9 . Female patient childbearing potential ( female patient achieve menarche ) must practice effective , reliable medically approve contraceptive regimen entire duration study , include followup period . At time last followup visit , patient must agree continue use adequate contraception method five month follow discontinuation eculizumab treatment . 10 . Able willing comply study procedure Exclusion : Any follow regarded criterion exclusion study : 1 . Known familial ADAMTS13 deficiency ( ADAMTS13 &lt; 5 % ) . 2 . Shiga toxin E.colirelated hemolytic uremic syndrome ( STECHUS [ know Shiga toxin + E.coli ] ) . 3 . History malignancy within five year screen . 4 . Known human immunodeficiency virus ( HIV ) infection . 5 . Identified drug exposurerelated HUS . 6 . Infectionrelated HUS . 7 . HUS relate bone marrow transplant ( BMT ) . 8 . HUS related vitamin B12 deficiency . 9 . Known Systemic Lupus Erythematosus ( SLE ) antiphospholipid antibody positivity syndrome . 10 . Plasma Therapy &gt; 5 week prior enrollment . 11 . Chronic dialysis ( defined dialysis regular basis renal replacement therapy endstage renal disease [ ESRD ] ) . 12 . Patients confirm diagnosis sepsis define positive blood culture within seven day screen visit treat antibiotic organism sensitive . 13 . Presence suspicion active untreated systemic bacterial infection , opinion Investigator confound accurate diagnosis aHUS impedes ability manage aHUS disease . 14 . Pregnancy lactation . 15 . History meningococcal/pneumococcal/gonococcal disease . 16 . Any medical psychological condition , opinion investigator , could increase patient 's risk participate study confound outcome study . 17 . Patients receive chronic intravenous immunoglobulin ( IVIg ) within eight week unless unrelated medical condition ( e.g. , Hypogammaglobinemia ) , chronic Rituximab therapy within 12 week screen visit . 18 . Patients receive immunosuppressive therapy steroid , mTOR inhibitor , calcineurin inhibitor ( e.g. , cyclosporine tacrolimus exclude unless : [ 1 ] part establish posttransplant antirejection regime , [ 2 ] patient confirm antiComplement Factor antibody antibody require immunosuppressive therapy [ 3 ] steroid use condition aHUS ( example asthma ) . 19 . Participation investigational drug trial device trial , procedure begin four week prior screen throughout entire trial 20 . Prior use eculizumab , hypersensitivity eculizumab , murine proteins one excipients .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Atypical Hemolytic-Uremic Syndrome</keyword>
</DOC>